William Abraham, MD was named the ​2022 HFSA Pioneer Award winner.

Dr. Abraham earned his medical degree from Harvard Medical School in Boston, Massachusetts,
following which he completed his residency in Internal Medicine and fellowships in
Cardiovascular Disease and Advanced Heart Failure/Transplant Cardiology at the University of
Colorado. He previously held leadership positions at the University of Colorado, the University
of Cincinnati, the University of Kentucky, and The Ohio State University. At Ohio State, Dr.
Abraham held several leadership positions including an Associate Dean position. As Director of
the Clinical Trials Management Organization, Dr. Abraham managed the College of Medicine’s
non-cancer clinical and translational research portfolio of more than 1,800 studies. As Division
Director, Dr. Abraham developed one of the largest and most successful academic programs of
Cardiovascular Medicine in the U.S.

Clinically, Dr. Abraham is board certified in Internal Medicine and Advanced Heart Failure and
Transplant Cardiology. He spends the majority of his clinical time managing acute and chronic
heart failure patients. Dr. Abraham has been recognized as one of the “Best Doctors in America”
for twenty consecutive years and is ranked among the top 10% of physicians nationally for
patient satisfaction.

Dr. Abraham’s research activities focus on elucidating basic mechanisms in heart failure and on
clinical drug and device development in heart failure. Dr. Abraham has received grants from the
National Institutes of Health, the American College of Cardiology, and the Aetna Quality Care
Foundation. He has made major contributions to advancing clinical science and patient care in
heart failure in several areas including neurohormonal mechanisms, cardiorenal interactions, and
the relationship between sleep and heart failure. Dr. Abraham has participated in all clinical and
regulatory phases of new drug and device development for heart failure. His work has led to the
approval and adoption of several new therapies for heart failure, including beta-blockers,
natriuretic peptides, cardiac resynchronization therapy, ultrafiltration, implantable hemodynamic
monitoring, transvenous phrenic nerve stimulation, cardiac contractility modulation, transcatheter
mitral valve repair, and baroreflex activation therapy.

Dr. Abraham has authored more than 1,000 original papers, abstracts, book chapters, and review
articles. His work has been published in high impact journals, including The New England
Journal of Medicine, The Lancet, the Journal of the American Medical Association, Circulation,
the European Heart Journal, and the Journal of the American College of Cardiology. Dr.
Abraham serves on the editorial boards of several major journals. He has been named to the
Clarivate Analytics (formerly Thomson Reuters) Highly Cited Researchers list and as one of The
World’s Most Influential Scientific Minds. In 2017, he received the Distinguished Scientist
Award from the American College of Cardiology.